BUZZ—US tech stocks mixed: tech giants rebound, chip stocks under pressure
路透社2026/11/09 13:11November 9 - ** After last week's setbacks, US artificial intelligence and technology stocks showed mixed movements in pre-market trading
** The tech-heavy Nasdaq 100 Index .NDX recorded a fourth consecutive weekly decline last Friday, as investors are seeking clues for the next step in artificial intelligence trading
Tech giants
** Microsoft MSFT.O rose 2%, while Meta META.O and Alphabet GOOGL.O rose 3% and 2%, respectively
Mixed performances among chip stocks
** Chip manufacturers saw mixed stock performance. NVIDIA NVDA.O dropped 5%, as investors assessed the aftermath of an internal investigation (link)—the investigation aimed to determine whether CEO Jensen Huang had ever been targeted by foreign intelligence agencies
** Intel INTC.O was steady, Marvell Technology MRVL.O edged up 0.3%, and Qualcomm QCOM.O fell 0.5%
** Advanced Micro Devices AMD.O rose 4.4%, and Broadcom AVGO.O gained 3.3%
NEOCLOUDS
** CoreWeave CRWV.O dropped 3.6%; at least two brokerages lowered their target price for the stock
** Peer Nebius NBIS.O fell 2.7%
Data center operators
** Core Scientific CORZ.O, Hut 8 Corp HUT.O and Cipher Digital CIFR.O declined between 2% and 3.7%
Cybersecurity
** CrowdStrike CRWD.O and Palo Alto PANW.O both climbed more than 1.2%
** Fortinet FTNT.O and Zscaler ZS.O each rose less than 1%
(To facilitate non-native English speakers, Reuters provides automated translations of its report into several other languages. Due to possible errors in automated translation or missing contextual information, Reuters does not guarantee the accuracy of automated translation text and it is offered only for reader convenience. Reuters assumes no liability for any damages or losses arising from use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
